BridgeBio Pharma, Inc. (BBIO)
68.56
+0.44
(+0.65%)
USD |
NASDAQ |
Oct 23, 16:00
68.53
-0.03
(-0.04%)
After-Hours: 20:00
BridgeBio Pharma Enterprise Value : 16.08B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 16.08B |
| October 22, 2026 | 15.99B |
| October 21, 2026 | 15.92B |
| October 20, 2026 | 15.88B |
| October 19, 2026 | 15.96B |
| October 16, 2026 | 15.66B |
| October 15, 2026 | 15.80B |
| October 14, 2026 | 15.37B |
| October 13, 2026 | 15.05B |
| October 12, 2026 | 15.53B |
| October 09, 2026 | 15.45B |
| October 08, 2026 | 15.39B |
| October 07, 2026 | 15.68B |
| October 06, 2026 | 15.77B |
| October 05, 2026 | 15.61B |
| October 02, 2026 | 15.82B |
| October 01, 2026 | 15.76B |
| September 30, 2026 | 15.54B |
| September 29, 2026 | 15.57B |
| September 28, 2026 | 15.70B |
| September 25, 2026 | 15.50B |
| September 24, 2026 | 15.63B |
| September 23, 2026 | 15.52B |
| September 22, 2026 | 16.21B |
| September 21, 2026 | 15.69B |
| Date | Value |
|---|---|
| September 18, 2026 | 15.70B |
| September 17, 2026 | 15.84B |
| September 16, 2026 | 16.03B |
| September 15, 2026 | 16.05B |
| September 14, 2026 | 16.83B |
| September 11, 2026 | 16.84B |
| September 10, 2026 | 16.85B |
| September 09, 2026 | 17.55B |
| September 08, 2026 | 17.29B |
| September 04, 2026 | 17.31B |
| September 03, 2026 | 17.42B |
| September 02, 2026 | 17.63B |
| September 01, 2026 | 17.64B |
| August 31, 2026 | 17.65B |
| August 28, 2026 | 17.65B |
| August 27, 2026 | 18.06B |
| August 26, 2026 | 18.19B |
| August 25, 2026 | 18.39B |
| August 24, 2026 | 18.52B |
| August 21, 2026 | 18.61B |
| August 20, 2026 | 18.89B |
| August 19, 2026 | 19.09B |
| August 18, 2026 | 18.90B |
| August 17, 2026 | 18.29B |
| August 14, 2026 | 18.29B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Pfizer Inc. | 222.94B |
| Ionis Pharmaceuticals, Inc. | 7.245B |
| Cytokinetics, Inc. | 8.598B |
| Vertex Pharmaceuticals, Inc. | 126.85B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -155.89M |
| Revenue (Quarterly) | 243.68M |
| Total Expenses (Quarterly) | 395.89M |
| EPS Diluted (Quarterly) | -0.7775 |
| Gross Profit Margin (Quarterly) | 93.68% |
| Profit Margin (Quarterly) | -63.97% |
| Earnings Yield | -5.21% |
| Normalized Earnings Yield | -5.204 |